Eine Phase-4-Studie zur Bewertung der Nebennierenfunktion bei hypogonadalen Männern, die 12 Monate lang mit JATENZO® behandelt wurden
Eine offene Phase-4-Studie zur Bewertung der primären Nebennierenfunktion (Glukokortikoidachse) bei hypogonadalen Männern, die 12 Monate lang mit JATENZO® behandelt wurden
TOL-CLAR-20024 is a Phase 4, multi-center, open-label safety study evaluating the potential effect of JATENZO on adrenal function in hypogonadal men treated with JATENZO for 12 months.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Following all screening activities and confirmation that the subject has met all eligibility requirements, JATENZO treatment for approximately 1 year will begin. The dose of JATENZO will be titrated using its standard dose-titration algorithms based on serum testosterone levels. The Treatment Period will consist of Visits 1 - 12, with cosyntropin stimulation test completed at Visit 9 (Day 169 ±7) and Visit 12 (Day 365 ±7). At each visit during the Treatment Period, subjects will be evaluated for signs and symptoms of adrenal insufficiency, occurrence of adverse events, and changes in concomitant medications. There will be a safety follow-up visit 2 weeks after completion of Visit 12.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 4
Kontakte und Standorte
Studienorte
-
-
Arizona
-
Tempe, Arizona, Vereinigte Staaten, 85281
- Alliance for Multispecialty Research
-
-
California
-
Lincoln, California, Vereinigte Staaten, 95648
- Clinical Trials Research
-
Long Beach, California, Vereinigte Staaten, 90805
- Long Beach Research Institute, LLC
-
Tarzana, California, Vereinigte Staaten, 91356
- Integrated Clinical Research
-
-
Florida
-
DeLand, Florida, Vereinigte Staaten, 32720
- Hillcrest Medical Research, LLC
-
Miami, Florida, Vereinigte Staaten, 33135
- Global Health Clinical Trial Crop
-
Miami, Florida, Vereinigte Staaten, 33176
- Reserka LLC
-
Ocala, Florida, Vereinigte Staaten, 34470
- Renstar Medical Research
-
Pompano Beach, Florida, Vereinigte Staaten, 33060
- Clinical Research Center of Florida
-
-
Georgia
-
Savannah, Georgia, Vereinigte Staaten, 31406
- Velocity Clinical Research
-
-
Maryland
-
Columbia, Maryland, Vereinigte Staaten, 21045
- Centennial Medical Group
-
-
Nebraska
-
Omaha, Nebraska, Vereinigte Staaten, 68134
- Velocity Clinical Research
-
-
New York
-
Garden City, New York, Vereinigte Staaten, 11530
- AccuMed Research Associates
-
Rochester, New York, Vereinigte Staaten, 14609
- Rochester Clinical Research, LLC
-
-
North Carolina
-
Durham, North Carolina, Vereinigte Staaten, 27701
- Velocity Clinical Research, Inc.
-
Hickory, North Carolina, Vereinigte Staaten, 28602
- Catawba Valley Medical Group, Inc.
-
Raleigh, North Carolina, Vereinigte Staaten, 27609
- Raleigh Medical Group
-
Statesville, North Carolina, Vereinigte Staaten, 28625
- Piedmont Healthcare, PA
-
Wilmington, North Carolina, Vereinigte Staaten, 28401
- Wilmington Health, PLLC
-
-
Texas
-
Austin, Texas, Vereinigte Staaten, 78759
- Velocity Clinical Research
-
DeSoto, Texas, Vereinigte Staaten, 75115
- Epic Medical Research LLC
-
Garland, Texas, Vereinigte Staaten, 75041
- VAST Clinical Research LLC
-
Mesquite, Texas, Vereinigte Staaten, 75149
- SMS Clinical Research LLC
-
-
Utah
-
Clinton, Utah, Vereinigte Staaten, 84015
- Alpine Research Organization, Inc.
-
Salt Lake City, Utah, Vereinigte Staaten, 84124
- Highland Clinical Research
-
-
Virginia
-
Norfolk, Virginia, Vereinigte Staaten, 23507
- Alliance for Multispecialty Research
-
-
Wisconsin
-
Kenosha, Wisconsin, Vereinigte Staaten, 53144
- Clinical Investigation Specialists, Inc.
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Subject must be a man 18 to 65 years of age, inclusive, with a previous clinical diagnosis of hypogonadism (signs/symptoms consistent with hypogonadism and a low T level as defined by established criteria at the time of diagnosis); subjects must also have at least 1 T level < 300 ng/dL at either Screen 1 or Screen 2.
- Subject must be naïve to androgen replacement therapy or washed out of prior androgen replacement therapies (wash out durations specified in exclusion criterion); that is, be willing to cease current T treatment, or currently not be taking T treatment.
- Subject agrees as part of signed informed consent to remain off all forms of T, except for dispensed study drug, throughout the entire study.
- Subject must have adequate venous access in the left or right arm to allow collection of blood samples.
- Subject must be able and willing to provide written informed consent and comply with the trial protocol and procedures.
Exclusion Criteria:
-
Subject will be excluded if 1 or more of the main exclusion is applicable:
-
Subject with a history of panhypopituitarism or multiple endocrine deficiencies (whether or not on stable doses of thyroid hormone and adrenal replacement hormones).
-
Subject with a current or prior history of AI.
-
Subject is currently receiving corticosteroids.
-
On the CST at Screen 3, the maximum serum total cortisol at both the 30- and 60-minute timepoint is ≤ 14 mcg/dL or has a baseline CBG outside the reference range.
-
Subject with a history of a short course (2 weeks or less) of any glucocorticoids within the past 3 months or anabolic steroids other than testosterone within the past 6 months.
-
Subject with a history of a protracted course of any glucocorticoid therapy (e.g., inhaled nasal steroids, inhaled oral steroids, topical steroids, injectable steroids such as joint injections) or anabolic steroids other than T. Enrolled subjects who take glucocorticoids while on study drug may be discontinued from the study at the discretion of the investigator in consultation with the sponsor.
-
Subject with a history of anabolic steroid abuse.
-
Subject with a diagnosis of hypogonadism who has received any topical (e.g., gel or patch), intranasal, or buccal T therapy within the previous 2 weeks, intramuscular T injection of short-acting duration (e.g., T enanthate, T cypionate) within the previous 4 weeks, intramuscular T injection of long-acting duration (e.g., AVEED®) within the previous 20 weeks, T implantable pellets (Testopel®) product within the previous 6 months or any prior use of an oral testosterone product.
-
Subject has received any drug as part of another research study within 30 days of initial dose administration in this study.
-
Subject has significant intercurrent disease (e.g., liver, kidney, inflammatory bowel disease, uncontrolled or poorly controlled heart disease, including hypertension, thromboembolism, congestive heart failure, or coronary heart disease, psychiatric illness, including severe depression), which in the opinion of the Investigator, would affect study participation or interpretation of study assessments.
-
Subject has untreated, severe obstructive sleep apnea.
-
Subject has clinically significant abnormal laboratory values, including serum transaminases > 2 × upper limits of normal (ULN), serum bilirubin > 1.5 × ULN (except subjects with Gilbert syndrome) and serum creatinine > 1.5 × ULN.
-
Subject has a HCT value of < 35% or > 50%.
-
Subject has a history of polycythemia, either idiopathic or associated with TRT treatment.
-
Subject is diabetic with a glycosylated hemoglobin > 8.5%.
-
Subject has a body mass index (BMI) ≥ 38 kg/m2.
-
Subject has had a recent (within 2 years) history of stroke, transient ischemic attack, or acute coronary event.
-
Subject has a mean (triplicate assessments) systolic blood pressure (sBP) > 140 mm Hg and/or diastolic blood pressure (dBP) > 90 mm Hg at screening (if prescribed antihypertensives, subject should be taking medications on the day of the screening visit with a sip of water).
-
Subject has had recent (within 2 years) history of angina or stent (coronary or carotid) placement.
-
Subject does not meet the requirements for concomitant medication as outlined below:
- If hypertensive, on a stable dose of antihypertensive medication for < 3 months
- If diabetic, on a stable dose of oral medication for < 2 months
- If on anticonvulsant therapy, on a stable dose for < 3 months
- If on lipid lowering medications, on a stable dose for < 3 months. Subject is expected to remain on a stable dose of lipid-lowering medication(s) throughout the study.
-
Subject has an abnormal prostate DRE (palpable nodules), elevated PSA (serum PSA > 4.0 ng/mL), I-PSS > 19 points at screening.
-
Subject has a history of, or current or suspected prostate cancer.
-
Subject has a history of, or current or suspected breast cancer.
-
Subject currently using a drug known to affect T levels, T metabolism or levels of T metabolites. These include: 5-alpha-reductase inhibitors (e.g., dutasteride, finasteride), estrogens, long-acting opioid analgesics (e.g., methadone hydrochloride, buprenorphine hydrochloride), human growth hormone (HGH) or over-the-counter supplements purported to "boost" testosterone, sexual function or improve prostate symptoms.
-
Subject use of dietary supplements such as saw palmetto or phytoestrogens and any dietary supplements that may increase total T, such as androstenedione or dehydroepiandrosterone within the previous 4 weeks.
-
Subject use of any over-the-counter "adrenal supplements".
-
Subject is not willing to stop all supplemental biotin 3 days prior to testing at intervals described in this protocol.
-
Subject currently using Megace, atypical anti-psychotics (e.g., clozapine, aripiorazole, asenapine, lumateperone, olanzapine, paliperidone, aripiprazole, ziprasidone, cariprazine, risperidone, pimavanserin, ioperidone, brexpiprazole, lurasidone, quetiapine) or chronic benzodiazepine use.
-
Subject has a history of abnormal bleeding tendencies or thrombophlebitis unrelated to venipuncture or intravenous cannulation within the previous 2 years.
-
Subject has history of abuse of alcohol or any drug substance within the previous 2 years.
-
Subject deemed to be a compliance risk or unlikely to keep clinic appointments.
-
Subject donated blood (≥ 500 mL) within the 12-week period before the initial study dose.
-
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: JATENZO® twice daily
JATENZO capsules will be provided in 3 dosage strengths: 158 mg, 198 mg, 237 mg twice daily |
158 mg JATENZO 198 mg JATENZO 237 mg JATENZO |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
CST Test
Zeitfenster: 6 months and 12 months
|
To estimate the proportion of subjects with an abnormal post-stimulation cosyntropin stimulation test (CST) serum total cortisol level after approximately 6 and 12 months of treatment with JATENZO |
6 months and 12 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Adrenal Insufficiency
Zeitfenster: 12 months
|
To estimate the proportion of subjects who develop primary adrenal insufficiency (AI) as assessed by clinical symptoms of AI and laboratory assessment of cortisol production after approximately 12 months of treatment with JATENZO |
12 months
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Hormone changes
Zeitfenster: 3 months and 6 months
|
To estimate the changes from baseline in estrogen (E), follicle stimulating hormone (FSH), and luteinizing hormon (LH) after approximately 3 and 6 months of treatment with JATENZO |
3 months and 6 months
|
|
Sperm analysis
Zeitfenster: 3 months and 6 months
|
To estimate the changes from baseline in sperm concentration, sperm motility, and total motile sperm count (TMSC) after approximately 3 and 6 months of treatment with JATENZO |
3 months and 6 months
|
|
Testis volume analysis
Zeitfenster: 3 months and 6 months
|
To estimate the changes from baseline in testicular size after approximately 3 and 6 months of treatment with JATENZO |
3 months and 6 months
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- TOL-CLAR-20024
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .